{"id":657277,"date":"2026-10-26T05:24:10","date_gmt":"2026-10-26T05:24:10","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/657277\/"},"modified":"2026-10-26T05:24:10","modified_gmt":"2026-10-26T05:24:10","slug":"how-glp-1-drugs-may-affect-crohns-disease-and-ulcerative-colitis","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/657277\/","title":{"rendered":"How GLP-1 Drugs May Affect Crohn\u2019s Disease and Ulcerative Colitis"},"content":{"rendered":"

Introduction<\/a>
Mechanistic and translational insights<\/a>
Associations with steroid use, hospitalization, and surgery<\/a>
Safety and tolerability<\/a>
Limitations and research gaps<\/a>
References<\/a>
Further reading<\/a><\/p>\n

Can drugs developed for diabetes and obesity also influence intestinal inflammation<\/a>? Researchers are examining immune signaling, gut barrier function, and patient outcomes to clarify their potential role in IBD care.<\/p>\n

\"Physician Image Credit: Jo Panuwat D \/ Shutterstock.com<\/p>\n

Introduction<\/p>\n

Glucagon-like peptide 1 (GLP-1) receptor agonist (RA) drugs are currently approved to treat type 2 diabetes (T2D), obesity, and other related metabolic conditions. In addition to their weight loss effects, GLP-1 RAs exhibit anti-inflammatory<\/a> activity in preclinical models, prompting investigation of their potential role in inflammatory bowel disease (IBD), an inflammatory disorder that can coexist with obesity and other metabolic conditions.1-3<\/p>\n

IBD, including Crohn\u2019s disease (CD) and ulcerative colitis (UC), is characterized by persistent gastrointestinal inflammation and disrupted intestinal epithelial barriers.1,3 Recent studies indicate that 15-40% of adults with IBD are obese, whereas 20-40% are overweight, reflecting broader population trends in obesity. Obesity-related inflammation may influence IBD activity and treatment response, but these prevalence estimates do not establish causation.1,2<\/p>\n

Metabolic comorbidities are also common in IBD: about 20% of IBD patients are also diagnosed with metabolic syndrome (MetS). The review by Maracle and colleagues reports rates of 38% in UC and 14% in CD, with prevalence varying across populations and diagnostic criteria. These summary figures should not be interpreted as a single population breakdown.1<\/p>\n

Type 2 diabetes has been reported in about 5% of IBD patients in large cohort studies, rather than representing a confirmed global prevalence. Estimates for metabolic dysfunction-associated steatotic liver disease (MASLD) range from 20-40% in IBD cohorts, showing the frequency of accompanying metabolic disease.1<\/p>\n

Mechanistic and translational insights<\/p>\n

Preclinical studies report GLP-1 receptor (GLP-1R) expression in intestinal intraepithelial lymphocytes and peripheral regulatory T-cells (Tregs). Experimental activation of GLP-1Rs inhibits T-cell receptor signaling and c, as well as nuclear factor-\u03baB (NF-\u03baB) activation and nuclear translocation in macrophages, reducing pro-inflammatory cytokines, including tumor necrosis factor \u03b1 (TNF-\u03b1) and interleukin 6 (IL-6).<\/p>\n

Animal studies suggest that GLP-1 RAs may also improve intestinal mucosal integrity by increasing the expression of tight junction proteins like claudin-1. However, these findings do not yet establish equivalent effects in patients with IBD.2,3<\/p>\n

Preclinical studies suggest GLP-1 signaling may reduce intestinal inflammation and support mucosal healing.3 In murine colitis models, liraglutide has been shown to limit disease-associated body weight loss and lower histological inflammation scores, alongside changes in gut immune cell activity and microbiome composition.3<\/p>\n

In one mouse study, liraglutide\u2019s protective effects involved group 3 innate lymphoid cells and increased IL-22 production.3 The relevance of these findings to human IBD remains unclear, and results vary by experimental model.\u00a0<\/p>\n

Some models indicate potential risks, such as increased E. coli translocation through sympathetic nervous system<\/a> activation.3 This experimental finding has not established an increased risk of bacterial translocation in treated patients.2,3<\/p>\n

Treating Obesity in IBD With GLP-1 Receptor AgonistsPlay<\/p>\n

Associations with steroid use, hospitalization, and surgery<\/p>\n

Several large registry and multi-database studies show that GLP-1 RA use is associated with improved clinical outcomes in IBD, particularly among patients with obesity or metabolic comorbidities.2 Some retrospective cohort studies report reduced rates of corticosteroid use, hospitalization, and IBD-related surgery in GLP-1 RA users compared to patients receiving other diabetes treatments or patients unexposed to GLP-1 RAs. Other studies report no significant differences in these outcomes; these were observational comparisons, without randomized placebo allocation.1-3<\/p>\n

In a Danish registry of 3,751 patients with IBD and T2D, a 48% lower incidence of a composite IBD outcome was reported among patients receiving GLP-1 RAs and\/or dipeptidyl peptidase-4 (DPP-4) inhibitors, compared with other antidiabetic treatments. The composite included oral corticosteroid use, TNF-\u03b1 inhibitor initiation, IBD-related hospitalization, and IBD-related surgery. An analysis restricted to GLP-1 RA exposure found a 44% lower incidence of this composite outcome.2,3 Significant reductions in oral corticosteroid use and hospitalizations were also reported in the Danish study.2,3<\/p>\n

In a United States cohort of patients with IBD and T2D, GLP-1 RA use was associated with a 63% lower hazard of colectomy in UC patients and a 45% lower hazard of IBD-related surgery in CD patients compared with other oral diabetes therapies. This study found no significant differences in oral or intravenous steroid use or initiation of advanced IBD therapy.2<\/p>\n

Metabolic benefits, including weight loss and improved glycemic control, are reported across cohorts, with meta-analytic data demonstrating approximately 9-12 kg of weight loss with semaglutide, liraglutide, or tirzepatide over follow-up generally exceeding three to six months. Follow-up periods varied across the underlying studies. These pooled estimates came from different patient groups and do not provide a direct comparison of the drugs or a uniform expected treatment response. Tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors.1,2,4<\/p>\n

Data from the Epidemiological Israeli IBD Research Nucleus (Epi-IIRN) registry showed an association between GLP-1 RA use and a 21% lower hazard of composite adverse IBD outcomes in patients with IBD and T2D. Subgroup analysis found no significant clinical benefit in non-obese individuals, suggesting that the association may differ by obesity status.2<\/p>\n

A recent meta-analysis also reported associations with lower risks of hospitalization and surgery in IBD patients with a body mass index (BMI) of at least 30 kg\/m2. These findings remain limited by the observational designs of the underlying studies, differences between cohorts, and potential confounding. It also remains unclear cannot whether improved outcomes reflect direct anti-inflammatory effects, weight loss, better metabolic control, or other differences between treated and untreated patients.1,4<\/p>\n

\"Woman Image Credit: Deucefleur \/ Shutterstock.com<\/p>\n

Safety and tolerability<\/p>\n

In general, some of the most common side effects associated with GLP-1 RA use include gastrointestinal (GI) discomfort characterized by transient nausea, vomiting, diarrhea, and constipation.1 These symptoms are also reported in IBD populations and sometimes lead to treatment discontinuation.<\/p>\n

Overall, available clinical data suggest that GLP-1 RAs are generally well tolerated in the IBD populations studied, with less information available for patients with severe disease. The available evidence cannot exclude uncommon harms or establish safety in severe or stricturing IBD.1,2<\/p>\n

In a Danish registry analysis including 4,430 GLP-1 RA-exposed IBD patients, a significantly lower risk of intestinal obstruction or ileus was observed when compared to unexposed individuals. This association does not establish that GLP-1 RAs prevent obstruction.1,2 Recognized treatment risks, such as cholelithiasis and cholecystitis, require standard clinical vigilance.2<\/p>\n

Limitations and research gaps<\/p>\n

Several large registry cohorts predominantly included patients with relatively mild IBD phenotypes, with limited evidence available for GLP-1 RA use in IBD patients with severe or biologic-refractory disease. Future studies should use standardized clinical measures, endoscopy, and inflammatory biomarkers to assess disease activity and mucosal healing, as administrative codes and treatment changes provide incomplete measures of intestinal inflammation.1-4<\/p>\n

Altered pharmacokinetics associated with delayed gastric emptying also warrant further study, as one case report showed increased thiopurine metabolite levels and abnormal liver function tests after tirzepatide initiation. Nevertheless, a single case cannot establish the frequency or mechanism of this interaction.2<\/p>\n

Effects on nutritional status and muscle mass also require study, particularly because malnutrition and sarcopenia can coexist with obesity in IBD.1,2<\/p>\n

References<\/p>\n

Maracle, B., Quan, S., Hamilton, P., et al. (2026). Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP\u20101 Receptor Agonists in Inflammatory Bowel Disease. Alimentary Pharmacology & Therapeutics 63(1); 17-39. DOI: 10.1111\/apt.70485. https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.70485<\/a>
\nColwill, M., Povlsen, S., Pollok, R., et al. (2025). Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential. Journal of Crohn\u2019s and Colitis 19(9). DOI: 10.1093\/ecco-jcc\/jjaf167. https:\/\/academic.oup.com\/ecco-jcc\/article\/19\/9\/jjaf167\/8256208<\/a>
\nThin, L., & Teh, W. L. (2025). GLP-1R Agonists and Their Therapeutic Potential in Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases: A Systematic Review of the Literature. Biomedicines 13(5); 1128. DOI: 10.3390\/biomedicines13051128. https:\/\/www.mdpi.com\/2227-9059\/13\/5\/1128<\/a>
\nBayoumy, A. B., Clarke, L. M., Deepak, P., et al. (2025). Glucagon-like peptide 1 receptor agonists and the clinical outcomes of inflammatory bowel disease: a systematic review and meta-analysis. Journal of Crohn\u2019s and Colitis 19(10). DOI: 10.1093\/ecco-jcc\/jjaf181. https:\/\/academic.oup.com\/ecco-jcc\/article\/19\/10\/jjaf181\/8280408<\/a><\/p>\n

Further Reading <\/p>\n

Last Updated: Oct 25, 2026<\/p>\n","protected":false},"excerpt":{"rendered":"IntroductionMechanistic and translational insightsAssociations with steroid use, hospitalization, and surgerySafety and tolerabilityLimitations and research gapsReferencesFurther reading Can drugs…\n","protected":false},"author":2,"featured_media":657278,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[13581,7308,4569,14546,163,15883,85,2876,46,42324,3477,75439],"class_list":["post-657277","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-crohns-disease","tag-gastroenterology","tag-glp-1","tag-gut-health","tag-health","tag-ibd","tag-il","tag-inflammatory-bowel-disease","tag-israel","tag-metabolic-health","tag-obesity","tag-ulcerative-colitis"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/657277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=657277"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/657277\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/657278"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=657277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=657277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=657277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}